Cytokines and cognitive function in first-episode drug-naïve MDD: an inflammation panel perspective

Area of Science:

• Neuroscience
• Psychiatry
• Immunology

Background:

• Cognitive impairment is a feature of major depressive disorder (MDD).
• The role of inflammation in MDD-related cognitive deficits is not fully understood.
• This study investigates cytokine profiles and their association with cognitive function in first-episode, drug-naïve MDD patients.

Purpose of the Study:

• To compare cytokine levels between MDD patients and healthy controls (HCs).
• To examine the relationship between specific cytokines and cognitive performance in both groups.
• To elucidate the inflammatory mechanisms underlying cognitive impairment in MDD.

Main Methods:

• 170 participants (101 MDD patients, 69 HCs) were enrolled.
• 27 cytokines were measured using Bio-Plex assay.
• Cognitive function was assessed using RBANS and TAS-20; mood via HAMD-17 and HAMA-14.

Main Results:

• MDD patients exhibited significantly poorer neurocognitive and social cognitive function than HCs.
• 26 out of 27 measured cytokines were elevated in MDD patients.
• A principal component (PC3) comprising RANTES, IL-9, MIP-1beta, TNF-alpha, IL-2, and IL-10 distinguished MDD from HCs (AUC=0.829).
• PC3 and its cytokines (RANTES, IL-9, IL-2, IL-10) negatively correlated with cognitive scores in HCs, but not in MDD patients.

Conclusions:

• First-episode drug-naïve MDD is associated with widespread cytokine elevation and cognitive deficits.
• Specific cytokines (RANTES, IL-9, IL-2, IL-10) are implicated in the inflammatory processes affecting cognition in MDD.
• The differing correlation patterns between cytokines and cognition in MDD versus HCs suggest distinct biological mechanisms.